DE69620756T2 - Kombinationstherapie zur behandlung des kongestiven herzversagens mit spironolacton und angiotensin ii-antagonist - Google Patents

Kombinationstherapie zur behandlung des kongestiven herzversagens mit spironolacton und angiotensin ii-antagonist

Info

Publication number
DE69620756T2
DE69620756T2 DE69620756T DE69620756T DE69620756T2 DE 69620756 T2 DE69620756 T2 DE 69620756T2 DE 69620756 T DE69620756 T DE 69620756T DE 69620756 T DE69620756 T DE 69620756T DE 69620756 T2 DE69620756 T2 DE 69620756T2
Authority
DE
Germany
Prior art keywords
angiotensin
receptor antagonist
spironolactone
combination therapy
heart failure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69620756T
Other languages
English (en)
Other versions
DE69620756D1 (de
Inventor
E Maclaughlan
R Schuh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Publication of DE69620756D1 publication Critical patent/DE69620756D1/de
Application granted granted Critical
Publication of DE69620756T2 publication Critical patent/DE69620756T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DE69620756T 1995-06-07 1996-06-05 Kombinationstherapie zur behandlung des kongestiven herzversagens mit spironolacton und angiotensin ii-antagonist Expired - Fee Related DE69620756T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48608995A 1995-06-07 1995-06-07
PCT/US1996/009342 WO1996040258A2 (en) 1995-06-07 1996-06-05 Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure

Publications (2)

Publication Number Publication Date
DE69620756D1 DE69620756D1 (de) 2002-05-23
DE69620756T2 true DE69620756T2 (de) 2002-11-14

Family

ID=23930539

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69620756T Expired - Fee Related DE69620756T2 (de) 1995-06-07 1996-06-05 Kombinationstherapie zur behandlung des kongestiven herzversagens mit spironolacton und angiotensin ii-antagonist

Country Status (16)

Country Link
US (1) US20040102423A1 (de)
EP (1) EP0831911B1 (de)
JP (1) JPH11509838A (de)
KR (1) KR19990022723A (de)
CN (1) CN1192696A (de)
AT (1) ATE216261T1 (de)
AU (1) AU6158096A (de)
BR (1) BR9608505A (de)
CA (1) CA2224222A1 (de)
CZ (1) CZ291268B6 (de)
DE (1) DE69620756T2 (de)
DK (1) DK0831911T3 (de)
ES (1) ES2175098T3 (de)
IL (1) IL122246A (de)
PT (1) PT831911E (de)
WO (1) WO1996040258A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
US6833381B2 (en) * 2000-02-18 2004-12-21 Takeda Chemical Industries, Ltd. TNF-α inhibitors
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
EP1465869B1 (de) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulatoren von lxr
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
EP1608319A4 (de) 2003-04-03 2007-02-28 Univ California Verbesserte hemmer für lösliche epoxidhydrolase
EP1765311A4 (de) 2004-03-16 2009-04-29 Univ California Verringerung von nephropathie mit hemmern der löslichen epoxid-hydrolase und von epoxyeicosanoiden
CN101084216B (zh) * 2004-10-20 2011-09-14 加利福尼亚大学董事会 可溶性环氧化物水解酶的改进抑制剂
JP2008520744A (ja) * 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 抗炎症性ピラゾロピリミジン
EP2004654B1 (de) 2006-04-04 2013-05-22 The Regents of the University of California Pyrazolopyrimidin-derivate zur verwendung als kinase-antagonisten
EP2051696A2 (de) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stabile flüssige levetiracetam-zusammensetzungen und verfahren
US20110160232A1 (en) * 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
US8193182B2 (en) * 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
KR101653842B1 (ko) * 2008-01-04 2016-09-02 인텔리카인, 엘엘씨 특정 화학 물질, 조성물 및 방법
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US8637542B2 (en) * 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US20110224223A1 (en) * 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
CA2730106A1 (en) 2008-07-08 2010-01-14 Intellikine, Inc. Kinase inhibitors and methods of use
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
US8697709B2 (en) 2008-10-16 2014-04-15 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
DK2384327T3 (da) 2009-01-30 2013-10-28 Takeda Pharmaceutical Forbindelse med kondenseret ring og anvendelse deraf.
WO2010129816A2 (en) 2009-05-07 2010-11-11 Intellikine, Inc. Heterocyclic compounds and uses thereof
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
EP2637669A4 (de) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Heterocyclische verbindungen und ihre verwendung
CA2824197C (en) 2011-01-10 2020-02-25 Michael Martin Processes for preparing isoquinolinones and solid forms of isoquinolinones
AU2012206945B2 (en) * 2011-01-11 2015-02-19 Dimerix Bioscience Pty Ltd Combination therapy
EP2678018A4 (de) 2011-02-23 2015-09-30 Intellikine Llc Kombination von kinasehemmern und verwendungen dafür
CN102816126A (zh) * 2011-06-07 2012-12-12 中国药科大学 具有心血管活性的胺磺酰芳基取代的三氮唑类衍生物、其制备方法及用途
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2842190A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
RU2014111823A (ru) 2011-08-29 2015-10-10 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
AU2012341028C1 (en) 2011-09-02 2017-10-19 Mount Sinai School Of Medicine Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
SG11201502331RA (en) 2012-09-26 2015-04-29 Univ California Modulation of ire1
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
BR112016007467B1 (pt) 2013-10-04 2022-09-20 Infinity Pharmaceuticals, Inc Compostos heterocíclicos e usos dos mesmos
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN113620958A (zh) 2014-03-19 2021-11-09 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
JP6861634B2 (ja) 2015-03-03 2021-04-21 イー，リチャード，ダブリュ． 眼疾患を処置するための組成物及び方法
CA2998469A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11147818B2 (en) 2016-06-24 2021-10-19 Infinity Pharmaceuticals, Inc. Combination therapies
KR102538999B1 (ko) 2016-06-29 2023-05-31 유니버시떼 드 몬트리얼 비아릴메틸 헤테로사이클
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3257390A (en) * 1963-06-12 1966-06-21 Merck & Co Inc Ring a unsaturated 21-hydroxy-3-oxo-17alpha-pregnane-17-carboxylic acid lactone diuretic agents
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3506100A1 (de) * 1985-02-18 1986-08-21 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha).7(alpha)-dithiosubstituierte spirolactone, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP0517812A4 (en) * 1990-02-13 1995-10-18 Merck & Co Inc Angiotensin ii antagonists incorporating a substituted benzyl element
WO1991015206A1 (en) * 1990-04-05 1991-10-17 E.I. Du Pont De Nemours And Company Treatment of glaucoma and ocular hypertension with imidazole angiotensin-ii receptor antagonists
CA2053148A1 (en) * 1990-10-16 1992-04-17 Karnail Atwal Dihydropyrimidine derivatives
US5049565A (en) * 1990-12-07 1991-09-17 Merck & Co., Inc. Microbial transformation process for preparing anti-hypertensive products
CA2109524A1 (en) * 1991-05-10 1992-11-11 Prasun K. Chakravarty Acidic aralkyl triazole derivatives active as angiotensin ii antagonists
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
US5264447A (en) * 1992-09-01 1993-11-23 Merck & Co., Inc. Angiotensin II antagonist
AU5449194A (en) * 1992-10-26 1994-05-24 Merck & Co., Inc. Combinations of angiotensin-ii receptor antagonists and diuretics
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases

Also Published As

Publication number Publication date
JPH11509838A (ja) 1999-08-31
CN1192696A (zh) 1998-09-09
CZ291268B6 (cs) 2003-01-15
EP0831911A2 (de) 1998-04-01
IL122246A0 (en) 1998-04-05
PT831911E (pt) 2002-09-30
DK0831911T3 (da) 2002-07-22
ATE216261T1 (de) 2002-05-15
AU6158096A (en) 1996-12-30
CZ384897A3 (cs) 1998-05-13
ES2175098T3 (es) 2002-11-16
WO1996040258A3 (en) 1997-01-23
BR9608505A (pt) 1999-07-06
WO1996040258A2 (en) 1996-12-19
DE69620756D1 (de) 2002-05-23
EP0831911B1 (de) 2002-04-17
CA2224222A1 (en) 1996-12-19
KR19990022723A (ko) 1999-03-25
US20040102423A1 (en) 2004-05-27
IL122246A (en) 2004-06-01

Similar Documents

Publication Publication Date Title
DE69620756T2 (de) Kombinationstherapie zur behandlung des kongestiven herzversagens mit spironolacton und angiotensin ii-antagonist
WO1996040255A3 (en) Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
NO975741D0 (no) Epoksy-steroidalaldosteronantagonist og antiotensin-II-antagonistkombinasjonsterapi for behandling av kongestiv hjertesvikt
NZ330889A (en) Cycloalkyl substituted imidazoles and their use in treating CSB/RK/p38 kinase mediated diseases
IE902139L (en) Imidazolyl alkenoic acids
AU640417B2 (en) Substituted 5-((tetrazolyl)alkenyl)imidazoles
PT85312A (en) Process for the preparation of angiotension ii receptor blocking imidazoles and of pharmaceutical
EP0437103A3 (de) Substituierte 5-(Alkyl)-carboxamid-Imidazole
NO175977C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive imidazolyl-alkensyrer
DE69625103T2 (de) Zweikammer-Herzschrittmachersystem unter Verwendung der Detektion ventrikulärer Fusionssystolen für die Verstellung der AV-Verzögerung bei der Therapie von hypertrophischen obstruktiven Kardiomyopathien
WO2004082599A3 (en) Combination of an aldosterone receptor antagonist and an anti-diabetic agent
CA2371012A1 (en) 4-(1h-pyrrol-1-yl) imidazoles
AU8534291A (en) Renal-selective angiotensin ii antagonists for treatment of hypertension
WO1992020651A3 (en) N-(heteroaryl)-imidazolyl-alkenoic acids
MX9709976A (es) Terapia de combinacion con espironolactona y antagonista de angiotensina ii para el tratamiento de fallas cardiacas congestivas.
HU9402429D0 (en) Pyrazolopyrimidin derivatives as angiotensin ii receptor antagonists
MY118704A (en) Process for preparation of eprosartan
MX9709978A (es) Terapia de combinacion de antagonista de aldosterona epoxi-esteroidal y antagonista de angiotensina ii para tratamiento de insuficiencia cardiaca congestiva.
MY108525A (en) Substituted imidazoles.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee